Janux Therapeutics, Inc. (JANX)
- Business Wire
Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference
SAN DIEGO, January 05, 2022--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference being held January 10 to 13.
- Simply Wall St.
We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- Business Wire
Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results
SAN DIEGO, November 09, 2021--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the quarter ended September 30, 2021.
